Robert E. Hoffman
CIK 1166288 · Chief Financial Officer · last filed 2026-07-13
Robert E. Hoffman is a Chief Financial Officer who has filed 71 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for ESPR, was dated Jul 13, 2026. Across all open-market trades the lifetime net is −$2.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $404 across reported positions. 39 SEC filings were submitted jointly with ARENA PHARMACEUTICALS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$404
11
71
-$2.28M
Filer Profile
6166 NANCY RIDER DRIVE
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. (ESPR) Delisted | Director | 0 | $3.18 | $0 | $0 | 4 | 2026-07-13 |
| FBLG | Director | — | $1.61 | — | $0 | 3 | 2026-06-23 |
| HURA | Director | — | $2.05 | — | $0 | 2 | 2026-02-17 |
| TuHURA Biosciences, Inc./NV (KTRA) Delisted | President, CEO and Interim CFO | 1,969 | $7.54 | $14.8K | $25.8K | 7 | 2023-09-01 |
| KURA | Director | — | $11.39 | — | $0 | 6 | 2021-06-23 |
| TuHURA Biosciences, Inc./NV (DMPI) Delisted | Director | — | — | — | $0 | 5 | 2020-06-30 |
| HRTX | CFO & SVP, Finance | 1,280 | $0.32 | $404 | -$1.15M | 5 | 2019-12-23 |
| Aravive, Inc. (ARAV) Delisted | Director | — | $0.04 | — | $0 | 3 | 2019-09-13 |
| CombiMatrix Corp (CBMX) Delisted | Director | 0 | — | — | $16.0K | 7 | 2017-11-16 |
| MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Director | 1,479 | — | — | $0 | 4 | 2017-05-23 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | SVP, Finance and CFO | 5,807 | $99.99 | $580.6K | -$1.17M | 16 | 2014-12-17 |
Recent Filings
71 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-13 | Esperion Therapeutics, Inc. (ESPR) Delisted | Disp (D) | −85,153 | $0 | EDGAR |
| 2026-06-23 | FBLG | Grant (A) | — | $0 | EDGAR |
| 2026-06-01 | Esperion Therapeutics, Inc. (ESPR) Delisted | Grant (A) | +79,873 | $0 | EDGAR |
| 2026-03-24 | — | Grant (A) | — | $0 | |
| 2026-02-17 | HURA | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | FBLG | Grant (A) | — | $0 | EDGAR |
| 2025-06-02 | Esperion Therapeutics, Inc. (ESPR) Delisted | Grant (A) | +5,280 | $0 | EDGAR |
| 2025-05-22 | — | Grant (A) | — | $0 | |
| 2025-04-02 | Esperion Therapeutics, Inc. (ESPR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-06 | HURA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.